[1]任彦文,向淑麟.甲磺酸萘莫司他在ICU高出血风险患者连续性血液净化中的应用[J].医学信息,2025,38(04):182-187.[doi:10.3969/j.issn.1006-1959.2025.04.035]
　REN Yanwen,XIANG Shulin.Application of Nafamostat Mesylate in Continuous Blood Purification for ICU Patients with High Bleeding Risk[J].Journal of Medical Information,2025,38(04):182-187.[doi:10.3969/j.issn.1006-1959.2025.04.035]
点击复制

甲磺酸萘莫司他在ICU高出血风险患者连续性血液净化中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年04期
页码:
182-187
栏目:
综述
出版日期:
2025-02-15

文章信息/Info

Title:
Application of Nafamostat Mesylate in Continuous Blood Purification for ICU Patients with High Bleeding Risk
文章编号:
1006-1959（2025）04-0182-06
作者:
任彦文1; 向淑麟2
1.右江民族医学院研究生学院，广西 百色 533000；2.广西壮族自治区人民医院/广西医学科学院重症医学科，广西 南宁 530021
Author(s):
REN Yanwen1;  XIANG Shulin2
1.Graduate School of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, China; 2.Department of Critical Care Medicine of the People’s Hospital of Guangxi Zhuang Autonomous Region/Guangxi Academy of Medical Sciences, Nanning 530021, Gu
关键词:
甲磺酸萘莫司他; 抗凝; 高出血风险; 连续性血液净化
Keywords:
Nafamostat mesylate;  Anticoagulant;  High bleeding risk;  Continuous blood purification
分类号:
R459.5
DOI:
10.3969/j.issn.1006-1959.2025.04.035
文献标志码:
A
摘要:
抗凝药物在连续性血液净化（CBP）中起着重要作用，目前常用的传统抗凝药物包括肝素、低分子肝素、枸橼酸等，这些药物都有相应的并发症及禁忌症。ICU中，当面对高出血风险患者，尤其是同时合并肝功能不全、高乳酸血症等情况时，上述抗凝药物或均存在局限性，而甲磺酸萘莫司他（Nafamostat Mesilate）具有安全、有效等特点，可作为高出血风险患者进行连续性血液净化的抗凝首选。但是，萘莫司他使用的监测指标及其优势、局限等仍需更多临床试验验证。本文主要总结高出血风险患者使用萘莫司他作为连续性血液净化治疗抗凝药物的应用，为临床决策等方面提供参考依据。
Abstract:
Anticoagulant drugs play an important role in continuous blood purification (CBP). At present, the commonly used traditional anticoagulant drugs include heparin, low molecular weight heparin, citric acid, etc. These drugs have corresponding complications and contraindications. In ICU, in the face of patients with high risk of bleeding, especially with liver dysfunction and hyperlactacidemia, the above anticoagulant drugs may have limitations. Nafamostat mesilate has the characteristics of safety and effectiveness, and can be used as the first choice of anticoagulation for continuous blood purification in patients with high risk of bleeding. However, the monitoring indicators used by nafamostat and its advantages and limitations still need more clinical trials to verify. This article mainly summarizes the application of nafamostat as an anticoagulant drug for continuous blood purification in patients with high bleeding risk, and provides reference for clinical decision-making.

参考文献/References:

[1]See E,Ronco C,Bellomo R.The future of continuous renal replacement therapy[J].Seminars in Dialysis,2021,34(6):576-585.[2]Rachoin J,Weisberg LS.Renal Replacement Therapy in the ICU[J].Critical Care Medicine,2019,47(5):715-721.[3]共识专家组,梅长林,丁峰.抗凝技术在危重症肾脏替代治疗应用的中国专家共识(2023年版)[J].中华肾脏病杂志,2023,39(2):155-164.[4]Khwaja A.KDIGO Clinical Practice Guidelines for Acute Kidney Injury[J].Nephron Clinical Practice,2012,120(4):c179-c184.[5]国家慢性肾病临床医学研究中心,中国医师协会肾脏内科医师分会,中国急性肾损伤临床实践指南专家组.中国急性肾损伤临床实践指南[J].中华医学杂志,2023,103(42):3332-3366.[6]Tsujimoto H,Tsujimoto Y,Nakata Y,et al.Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy[J].Cochrane Database Syst Rev,2020,12(12):D12467.[7]Zarbock A,Kullmar M,Kindgen-Milles D,et al.Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial[J].JAMA,2020,324(16):1629-1639.[8]Legrand M,Tolwani A.Anticoagulation strategies in continuous renal replacement therapy[J].Seminars in Dialysis,2021,34(6):416-422.[9]王平,谢枫,李辉,等.不同抗凝技术配合血液净化在ICU高危出血风险患者中的应用价值[J].新疆医学,2023,53(3):294-296.[10]北村伸哉,张凌.甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用[J].华西医学,2018,33(7):801-805.[11]Kamijo H,Mochizuki K,Nakamura Y,et al.Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan[J].Journal of Clinical Medicine,2020,9(8):2629.[12]Lin Y,Shao Y,Liu Y,et al.Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis[J].Ren Fail,2022,44(1):1263-1279.[13]Sadahiro T,Yuzawa H,Kimura T,et al.Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study[J].Contrib Nephrol,2018,196:209-214.[14]Abe M,Shiga H,Tatsumi H,et al.Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes[J].Renal replacement therapy,2022,8(1):11-58.[15]上海市医学会肾脏病专科分会《甲磺酸萘莫司他的血液净化抗凝应用专家共识》编写组.甲磺酸萘莫司他的血液净化抗凝应用专家共识[J].上海医学,2024,47(3):129-143. [16]Oh HS,Kim T,Gu D,et al.Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis[J].Molecules,2022,27(6):1881.[17]Doi K,Nishida O,Shigematsu T,et al.The Japanese clinical practice guideline for acute kidney injury 2016[J].Clin Exp Nephrol,2018,22(5):985-1045.[18]中华医学会肾脏病学分会专家组.连续性肾脏替代治疗的抗凝管理指南[J].中华肾脏病杂志,2022,38(11):1016-1024. [19]卢文婷,向淑麟,任彦文,等.甲磺酸萘莫司他在高出血风险患者连续性血液净化中的抗凝应用效果观察[J].中国临床新医学,2024,17(1):74-78.[20]庄冰,叶红,曹红娣,等.注射用甲磺酸萘莫司他用于血液透析抗凝治疗的多中心随机对照研究[J].中国血液净化,2022,21(10):739-743.[21]Liu K,Li Z.Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure[J].World Journal of Clinical Cases,2024,12(1):68-75.[22]王婷,李敏,曾萍,等.萘莫司他与阿加曲班在≥75岁病人连续性肾脏替代治疗期间的抗凝效果对比[J].实用老年医学,2023,37(12):1224-1227.[23]敖广宇,黄兰,陈亭宇,等.血液透析中甲磺酸萘莫司他抗凝的血药浓度与抗凝有效性观察[J].中国血液净化,2023,22(8):579-583.[24]Isayama N,Matsumura G,Uchimura Y,et al.Utility and safety of nafamostat mesilate for anticoagulation in dogs[J].Veterinary Medicine and Science,2023,9(1):68-75.[25]Lee JH,Park JH,Jang JH,et al.The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation[J].Acute and Critical Care,2022,37(2):177-184.[26]Liu D,Zhao J,Xia H,et al.Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study[J].European Journal of Medical Research,2024,29(1):72.[27]Choi JY,Kang YJ,Jang HM,et al.Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial[J].Medicine (Baltimore),2015,94(52):e2392.[28]张艳,殷娜,丁皓姝.甲磺酸萘莫司他抗凝对外科重症监护病房患者连续性肾脏替代治疗有效性及安全性回顾性研究[J].世界临床药物,2022,43(9):1148-1153.[29]胡雪峰,刘志刚,李鹏,等.萘莫司他对血液透析高危出血倾向患者的治疗效果研究[J].长春中医药大学学报,2024,40(1):99-102.[30]Nakada K,Hirai D,Seta K,et al.Nafamostat Mesylate for the Hypercoagulable State of SARS-CoV-2 With Renal Replacement Therapy: A Case Report[J].Cureus,2024,16(1):e52641.[31]Hernández-Mitre MP,Tong SYC,Denholm JT,et al.Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review[J].Clinical Pharmacokinetics,2022,61(10):1331-1343.[32]Zhang W,Bai M,Yu Y,et al.Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis[J].Crit Care,2019,23(1):22.[33]朱倩莹,程立新,黄兰,等.甲磺酸萘莫司他体外抗凝在脓毒症合并急性肾损伤患者连续性肾脏替代治疗中的应用评价[J].华西医学,2023,38(5):718-723.[34]Lee B,Cho JY,Han H,et al.Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure[J].HPB,2022,24(9):1569-1576.[35]丁家荣,张欢,谌卫,等.甲磺酸萘莫司他在高危出血风险连续肾脏替代治疗患者的抗凝应用[J].临床肾脏病杂志,2024,24(2):96-102.[36]Kameda S,Maeda A,Maeda S,et al.Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study[J].BMC Nephrology,2024,25(1):69.[37]安琪,经天宇,查镜凯,等.基于决策树模型的甲磺酸萘莫司他与普通肝素用于连续肾脏替代治疗抗凝的最小成本分析[J].中国循证医学杂志,2023,23(2):139-146.[38]Kim HS,Lee KE,Oh JH,et al.Cardiac arrest caused by nafamostat mesilate[J].Kidney Research and Clinical Practice,2016,35(3):187-189.[39]Koniari I,Kounis NG.Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?[J].Kidney Res Clin Pract,2017,36(1):105-106.[40]Ookawara S,Ito K,Morishita Y.Sustained Deterioration of Hepatic Oxygenation After Nafamostat Mesilate-Induced Anaphylactic Shock During Hemodiafiltration[J].Artif Organs,2018,42(6):674-675.[41]Kim J,Park JY,Jang SH,et al.Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis[J].Allergy, Asthma & Immunology Research,2021,13(3):517.[42]Kodama K,Imai T,Asai Y,et al.Incidence and risk factors for hyperkalaemia in patients treated for COVID‐19 with nafamostat mesylate[J].Journal of Clinical Pharmacy and Therapeutics,2022,47(7):1070-1078.[43]Choi JH,Byun SY,Nam A,et al.Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs[J].Journal of Veterinary Emergency and Critical Care,2018,28(2):122-129.[44]Lim JY,Kim JB,Choo SJ,et al.Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin[J].The Annals of Thoracic Surgery,2016,102(2):534-539.[45]李婷婷,胡高峰,李臣宾,等.用于低分子量肝素治疗监测的抗Xa因子活性的性能验证和校准方法探讨[J].血栓与止血学,2023,29(3):103-110.

相似文献/References:

[1]周井铎,田康爱,孟 震,等.急性脾肾梗死伴房颤1例并文献复习[J].医学信息,2018,31(15):191.[doi:10.3969/j.issn.1006-1959.2018.15.066]
[2]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Journal of Medical Information,2018,31(04):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
[3]吴小燕,刘 杰,刘文锋,等.稳定性冠心病合并心房颤动患者抗栓策略的Meta分析[J].医学信息,2020,33(03):82.[doi:10.3969/j.issn.1006-1959.2020.03.024]
　WU Xiao-yan,LIU Jie,LIU Wen-feng,et al.Meta-analysis of Antithrombotic Strategies for Stable Coronary Heart Disease with Atrial Fibrillation[J].Journal of Medical Information,2020,33(04):82.[doi:10.3969/j.issn.1006-1959.2020.03.024]
[4]赵鑫龙,杨杰孚.华法林药物基因组学的应用[J].医学信息,2021,34(20):50.[doi:10.3969/j.issn.1006-1959.2021.20.012]
　ZHAO Xin-long,YANG Jie-fu.Application of Warfarin Pharmacogenomics[J].Journal of Medical Information,2021,34(04):50.[doi:10.3969/j.issn.1006-1959.2021.20.012]

更新日期/Last Update: 1900-01-01